Eidos Therapeutics Initiates ATTRibute-CM, a Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month Endpoint

February 27, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search